This week, ZenPharm, the Maltese joint venture with Canadian cannabis producer, Zenabis Global, received its Maltese licence to process cannabis for medicinal use and research purposes out of its Hal Far Industrial Estate premises.
Kurt Farrugia, CEO of Malta Enterprise – the national economic development agency that assisted the company to set up locally – considers this “an important milestone for Malta’s medical cannabis industry.”
“We are gaining momentum with the production of cannabis for medical use in Malta,” he wrote. “Zenabis – a Maltese joint venture and partner of Zenpharm, have received a licence for the production of medical cannabis in their facility in Hal Far, Malta.”
The CEO said that the issuing of the second licence for the production of cannabis for medical use shows that “Malta is becoming a centre of excellence in such an important emerging sector.”
“Those companies strive hard to achieve the Medicine’s Authority pharmaceutical standards. Now that they do, patients can rest assured that the Made in Malta product is top quality. A gold standard for the industry. This is indeed a proud moment.”
Through its licence, ZenPharm plans to ship around 500kg of cannabis out of Malta annually to EU countries, with the largest market being Germany.
Featured Image:
Kurt Farrugia / LinkedIn
Alison Micallef appointed CEO at Malta Development Bank
She steps into the new role effective immediately.
Impact beyond profit: CSR in Malta is a must in 2025
Nowadays, corporate social responsibility can no longer take a backseat in your business's vision.
Malta’s private equity sector urged to seize opportunities at high-level CEO seminar
Panellists highlighted Malta’s potential as a destination for private capital, citing its English-speaking workforce, regulatory accessibility, and strategic location.
Ronald Attard takes on expanded role as Managing Partner for Risk Management at EY Europe Central
He has built experience in management accounting, corporate finance, and mergers and acquisitions.
